MedTrace Logo

Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate Cancer

NCT00455624 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2013-07-11

No results posted yet for this study

Summary

The purpose of this study is to find out if androgen deprivation therapy affects insulin, cardiac risk factors such as cholesterol level, and body fat and muscle.

Conditions

Interventions

DRUG

Androgen deprivation therapy

According to standard medical care

Sponsors & Collaborators

Principal Investigators

  • Matthew Smith, MD, PhD · Massachusetts General Hospital

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30
Primary Completion
2006-05-31
Completion
2006-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00455624 on ClinicalTrials.gov